Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study.

- Christophe Weber, Takeda President and Chief Executive Officer Highlights of Takeda's 2025 Annual Integrated Report Groundbreaking science ...

Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, ...

Japan’s largest pharma company Taked today announced that all primary and secondary endpoints were met in two Phase III ...

- Christophe Weber, Takeda President and Chief Executive Officer Highlights of Takeda’s 2025 Annual Integrated Report Groundbreaking science In FY2024, Takeda invested USD 4.9 billion in research and ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

NORTHAMPTON, MA / ACCESS Newswire / July 8, 2025 / Takeda is pleased to announce the publication of its 2025 Annual Integrated Report. The Report, available in both English and Japanese, sets out:How ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results ...